Scott Hayton

Scott joined Flagship in 2022 as an Operating Principal, working to turn innovative ideas into breakthrough bioplatform companies. As a member of Jake Rubens’s venture-creation team, he makes sure the day-to-day operations of Flagship’s early-stage companies run smoothly, and he develops strategies to maximize their value potential. Scott was a member of the founding team of Quotient Therapeutics, where he served as its founding Chief Operating Officer from 2022 to 2025.

Prior to joining Flagship, Scott spent nearly a decade as a strategy consultant at McKinsey & Company, where he helped biopharma companies wrestle with large strategic questions. While there, he led McKinsey’s Neuroscience practice and spent a one-year secondment at Gates Ventures, Bill Gates’ executive office, as a director of special projects and helped design the initial Alzheimer’s disease strategy and philanthropic investments.

Scott holds a Ph.D. in Neuroscience from Queen’s University and did a postdoctoral fellowship at Stanford University, where he worked with Robert Malenka and Thomas Sudhof (2013 Nobel Laureate). He has published articles in Cell, Neuron, and the Journal of Neuroscience.